Camlin Fine Sciences Ltd (CAMLINFINE) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Camlin Fine Sciences delivered fairly good results despite a challenging global environment marked by tariffs and geopolitical instability.
- The company achieved a 15% year-on-year growth in revenue from continuing operations, reaching 1,660 crore, driven by volume growth and the performance of the vanillin business.
- The blends business experienced healthy growth, particularly in North America and India, with a 17-18% year-on-year increase, reaching 878 crore.
- The aroma business, primarily vanillin, continued its growth momentum, contributing 176 crore in revenue for the quarter.
- The company improved its EBITDA margin to 12.5%, reaching 208 crore compared to 184 crore in the same quarter last year.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.